MARLBOROUGH, Mass.,
June 25, 2014 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering, developing and
commercializing innovative therapies addressing major unmet medical
needs using RNA-targeted technologies, today announced the Company
is set to join the Russell
Microcap® Index when Russell
Investments reconstitutes its comprehensive set of U.S. and global
equity indexes on June 27, 2014,
according to a preliminary list of additions posted June 13, 2014 on
www.russell.com/indexes.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Membership in the Russell Microcap Index, which remains in place
for one year, means automatic inclusion in the appropriate growth
and value style indexes. Russell determines membership for its
equity indexes primarily by objective, market-capitalization
rankings and style attributes.
"We are pleased with the anticipated inclusion in the Russell
Microcap Index," said Dr. Geert
Cauwenbergh, President and CEO of RXi Pharmaceuticals. "This
listing provides another positive step forward, for our Company and
its shareholders, increasing visibility and awareness amongst
institutional investors."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Russell calculates more than 700,000
benchmarks daily covering approximately 98 percent of the
investable market globally, 80 countries and more than 10,000
securities. Approximately $5.2
trillion in assets are benchmarked to the Russell
Indexes.
Annual reconstitution of Russell Indexes captures the 4,000
largest U.S. stocks as of the end of May, ranking them by total
market capitalization to create the Russell
3000® Index and Russell Microcap Index.
These investment tools originated from Russell's multi-manager
investment business in the early 1980s when the company saw the
need for a more objective, market-driven set of benchmarks in order
to evaluate outside investment managers.
About Russell
Russell Investments (Russell) is a global asset manager and one
of only a few firms that offers actively managed multi-asset
portfolios and services that include advice, investments and
implementation. Russell stands with institutional investors,
financial advisors and individuals working with their
advisors—using the firm's core capabilities that extend across
capital market insights, manager research, portfolio construction,
portfolio implementation and indexes to help each achieve their
desired investment outcomes.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi (sd-rxRNA®) platform. Therapeutics
that use RNA interference, or "RNAi," have great promise
because of their ability to down-regulate the expression of
specific genes that may be over-expressed in disease conditions.
Building on the pioneering work of scientific founder and Nobel
Laureate Dr. Craig Mello, a member
of the RXi Scientific Advisory Board, RXi's first RNAi product
candidate, RXI‑109, entered into human clinical trials in
June 2012 and is currently being
evaluated in Phase 2 clinical trials. RXI‑109 targets
connective tissue growth factor (CTGF) to reduce dermal scarring
(fibrosis). RXi's sd‑rxRNA oligonucleotides are designed for
therapeutic use and have drug-like properties, such as high
potency, target specificity, serum stability, reduced immune
response activation, and efficient cellular uptake. These hybrid
oligonucleotide molecules combine the beneficial properties of
conventional RNAi and antisense technologies. This allows
sd‑rxRNAs to achieve efficient cellular uptake and potent,
long-lasting intracellular activity. For more information, please
visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks and
uncertainties: the risk that we may not be able to
successfully develop our candidates, or that development of
RNAi-based therapeutics may be delayed or not proceed as planned,
or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed,
risks related to the development and commercialization of products
by our competitors, the risk related to our ability to control the
timing and terms of collaborations with third parties, and the
possibility that other companies or organizations may assert patent
rights preventing us from developing our products. Actual results
may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
Tamara
McGrillen
508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation